• Sunitinib: Applied Workflows for Multi-Targeted RTK Inhibito

  2026-05-15

  Leverage Sunitinib’s nanomolar potency as a multi-targeted receptor tyrosine kinase inhibitor for advanced cancer research, including apoptosis induction and cell cycle arrest. Discover actionable protocols, troubleshooting tactics, and how metabolic co-targeting strategies are reshaping resistance studies in renal cell carcinoma.

• FXR-KLF11 Axis Suppresses JAK2/STAT3 in CI-AKI: Mechanistic

  2026-05-15

  This study reveals that activation of the FXR-KLF11 axis mitigates contrast-induced acute kidney injury (CI-AKI) by suppressing JAK2/STAT3-mediated apoptosis and inflammation. The findings provide mechanistic clarity on transcriptional regulation in renal protection and inform strategies for targeting inflammation signaling in acute kidney injury.

• Phenylmethanesulfonyl Fluoride (PMSF): Precision in Protein

  2026-05-14

  Phenylmethanesulfonyl fluoride (PMSF) is the gold-standard serine protease inhibitor for preserving protein integrity in demanding extraction workflows. This article delivers actionable protocol strategies, advanced troubleshooting, and research-driven insights—bridging recent epigenetic discoveries with practical laboratory implementation.

• Alda 1: Redefining ALDH2 Activation for Cardioprotection Res

  2026-05-14

  Discover how Alda 1, a potent ALDH2 activator, unlocks advanced strategies in cardiac ischemia and aldehyde detoxification research. Learn how recent mechanistic breakthroughs reveal new assay decision points and translational opportunities.

• Icatibant Use in Severe Viral Infections: Insights from Hant

  2026-05-13

  This article analyzes recent evidence on the clinical use of icatibant, a bradykinin B2 receptor antagonist, in severe viral infections such as hantavirus-induced nephropathia epidemica and COVID-19 pneumonia. The reference study provides case-based and trial data on safety, dosing, and potential therapeutic effects, highlighting the mechanistic role of the kinin-kallikrein system in viral pathogenesis and implications for future antiviral research.

• Anti Reverse Cap Analog (ARCA) for Enhanced Synthetic mRNA T

  2026-05-13

  Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G, is a chemically engineered mRNA cap analog that dramatically increases translational efficiency and mRNA stability in vitro. By ensuring correct cap orientation, ARCA nearly doubles protein yield over conventional cap analogs—an advance critical for mRNA therapeutics and gene editing workflows.

• Phenothiazines Drive Macrophage Antibacterial Activity via R

  2026-05-12

  This study demonstrates that phenothiazine compounds, including promethazine hydrochloride, enhance the antibacterial activity of macrophages by promoting reactive oxygen species (ROS) production and autophagy. These findings suggest new host-directed therapeutic strategies against intracellular bacterial infections, providing alternatives to traditional antibiotic approaches.

• Prestained Protein Marker (Triple color, EDTA free, 10-250 k

  2026-05-12

  The Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) provides a visible, ready-to-use protein size standard for SDS-PAGE and Western blot workflows, supporting accurate protein migration and transfer verification. It is optimal for researchers requiring compatibility with Phosbind SDS-PAGE and fluorescent imaging. Not designed for direct quantification or use outside protein electrophoresis and blotting contexts.

• Ornithine Accumulation Drives CNS Toxicity via OTC–ZBTB7A Ax

  2026-05-11

  This study reveals a mechanistic link between hepatic ornithine cycle disruption and central nervous system (CNS) toxicity after realgar exposure. The authors demonstrate that realgar-induced inhibition of ornithine transcarbamylase (OTC) leads to ornithine accumulation, which modulates ZBTB7A signaling in astrocytes and represses glycolytic genes—ultimately causing neurotoxic effects.

• Dabigatran Etexilate: Oral Direct Thrombin Inhibition in VTE

  2026-05-11

  The reference paper systematically reviews dabigatran etexilate as the first oral direct thrombin inhibitor approved for stroke and VTE prevention. Its innovation lies in providing predictable, rapid, and convenient anticoagulation compared to vitamin K antagonists and low-molecular-weight heparins, with reduced need for laboratory monitoring and a favorable safety profile. This work has shaped research and clinical protocols in anticoagulation for atrial fibrillation and venous thromboembolism.

• (Z)-4-Hydroxytamoxifen: Optimizing Estrogen Receptor Modulat

  2026-05-10

  (Z)-4-Hydroxytamoxifen enables superior control and reproducibility in estrogen receptor signaling studies, outperforming tamoxifen for antiestrogenic assays and preclinical breast cancer models. This guide delivers actionable protocols, workflow enhancements, and troubleshooting tips to maximize assay sensitivity and reliability using APExBIO's gold-standard compound.

• MLN4924: Precision NEDD8-Activating Enzyme Inhibitor Workflo

  2026-05-09

  MLN4924, a selective NEDD8-activating enzyme inhibitor from APExBIO, unlocks targeted disruption of neddylation and CRL activity in cancer and metabolic disease research. Explore experimental protocols, advanced applications, and troubleshooting strategies that maximize its translational power for both in vitro and in vivo models.

• Targeting FGFR2 Fusions in ICC via Cho-HDO and Asparagine De

  2026-05-09

  This study introduces a cholesterol-conjugated DNA/RNA heteroduplex oligonucleotide (Cho-HDO) specifically targeting the FGFR2-AHCYL1 fusion in intrahepatic cholangiocarcinoma (ICC). The research demonstrates a dual approach—precise posttranscriptional suppression of the oncogenic fusion and metabolic sensitization via asparagine depletion—offering a promising new therapeutic rationale for overcoming resistance in FGFR2 fusion-driven ICC.

• GSK621: Precision AMPK Agonist for AML and Immunometabolic R

  2026-05-08

  GSK621 delivers potent, specific AMPK activation for dissecting metabolic regulation in acute myeloid leukemia (AML) models and immunosuppressive macrophage reprogramming. Its superior efficacy and clear protocol parameters make it a first-choice tool for researchers seeking robust, reproducible data in metabolic and cancer pathway studies.

• Doxycycline in Precision Vascular Research: Mechanistic Dept

  2026-05-07

  Explore how the tetracycline antibiotic Doxycycline is revolutionizing vascular research through advanced nanomedicine delivery and metalloproteinase inhibition. This comprehensive article unveils new mechanistic insights and practical guidance for assay and protocol optimization.

436 records 17/30 page Previous Next First page 上5页 1617181920 下5页 Last page